Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
=== Secondary protection === Secondary protection refers to early detection of disease, potentially while still asymptomatic, to allow positive intervention to prevent, delay, or attenuate the symptomatic clinical condition. This includes the following: retinoids (e.g., tretinoin), antioxidants (e.g., topical vitamin C, oral supplements, CoQ10, Lipoic acid), estrogens, growth factors, and cytokines. There are various forms of topical retinoids. Tretinoin, a retinoid, is widely considered to be the most efficacious treatment for photoaging by dermatologists due to consistent evidence from several randomized clinical trials. Retinoids are vitamin A derivatives that bind to retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Binding to these receptors induces a cascade of cellular processes that ultimately lead to increased collagen production and epidermal thickening, reducing the appearance of skin sagging and wrinkling. Tretinoin is also efficacious for the treatment of acne. Adapalene and tazarotene are also third-generation synthetic retinoids that are used for the treatment of acne. Adapalene has not been widely studied or proven for use in photoaging. However, it has been used off-label for that purpose. Tazarotene has been proven to be efficacious in the treatment of photoaging. Retinoid derivatives, known as retinol and retinal, are often used in over-the-counter cosmeceutical products for anti-aging purposes. The form of and retinal are metabolized in the skin to retinoic acid, which can then act on the RARs and RXRs.
==== Absorption ==== Following oral administration of lisinopril, peak serum concentrations of lisinopril occur within about seven hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. The peak effect of lisinopril is about 6 hours after administration for most people. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not undergo metabolism and the absorbed drug is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% (reduced to 16% in people with New York Heart Association Functional Classification (NYHA) Class II–IV heart failure), with large interpatient variability (6 to 60%) at all doses tested (5 to 80 mg). Lisinopril absorption is not affected by the presence of food in the gastrointestinal tract. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Multiple doses of lisinopril in rats result in little or no accumulation in brain tissue.
He plants several bombs on Earth and challenges S.P.D.'s Earth unit to find them as part of a game he played on previous planets before he destroyed them while using his tiny size to hide. After Ban finds him disguised as a walkie-talkie, Byz Goa retaliates by piloting a Kaijuki called Cannon Gladiator 2 (キャノングラディエーター2, Kyanon Guradiētā Tsū), only to be deleted by Dekaranger Robo. Byz Goa is voiced by Tomokazu Seki (関 智一, Seki Tomokazu). Dradian Goldom (ドラド星人ゴルドム, Dorado Seijin Gorudomu): A criminal from Planet Drad who kidnaps Attika Alpachi's son to force him into taking a city block hostage while Goldom robs a nearby bank in the confusion, only for the Dekarangers to realize the truth. Goldom attempts to escape in his Kaijuki, Terrible Terror 2 (テリブルテーラー2, Teriburu Tērā Tsū), but is deleted by Deka Bike Robo. Goldom is voiced by Takaya Kuroda (黒田 崇矢, Kuroda Takaya). Amoreian Baachiyo (アモーレ星人バーチョ, Amōre Seijin Bacho): A hermaphroditic spider-themed criminal and stalker from Planet Amore who possesses four tendrils capable of firing spider silk-like threads to restrain targets and whose people earned a reputation for being overly passionate and "too in love". Following a brief encounter with Tetsu while the officer was working undercover as a woman, falling in love with "her", and eventually metamorphosing from his powerless immature form to his stronger adult form, Baachiyo stalks Swan Shiratori with the belief that she was the person he fell in love with.
=== Marketing === Liraglutide was approved by the US Food and Drug Administration (FDA) in 2014, and by the European Medicines Agency (EMA) in 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition. Liraglutide was approved by the FDA in 2019, for treatment of children aged ten years of age or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000. Novo Nordisk made deals with generic manufacturers to enter the United States market in 2024. The FDA approved the first generic liraglutide in December 2024, and granted the approval to Hikma Pharmaceuticals USA
Sources: en.wikipedia.org
=== Campaign finances reports === Many parties failed to report their campaign finances in a timely fashion, leading to suspicion over the use of the funds. On 21 November 2021, the ONPE sent auditors to supervise the management of party funds. The first parties scheduled to be audited are the Purple Party, Alliance for Progress, We Are Peru, and Popular Force. Later, Go on Country, Free Peru, and Together for Peru will be audited.
== Biosynthesis == Alamethicin biosynthesis is hypothesized to be catalyzed by alamethicin synthase, a Nonribosomal peptide synthase (NRPS) first isolated in 1975. Although there are several sequences of the alamethicin peptide accepted, evidence suggests these all follow the general NRPS mechanism with small variations at select amino acids. Beginning with the acylation of the N terminal of the first aminoisobutiric acid on the ALM synthase enzyme by Acetyl-CoA, this is followed by the sequential condensation of amino acids by each modular unit of the synthetase. Amino acids are initially adenylated by an “adenylylation” (A) domain before being attached by a thioester bond to an Acyl Carrier Protein-like Peptidyl carrier protein. The growing chain is attached to the amino acid bearing PCP by the "condensation" (C) domain, followed by another round of the same reactions by the next module.
=== Indian Ocean === As of 2022, India is one of five countries that produced 50% of the world fish bladder supply and 70% of its value. The Indian swim bladder trade dates back to the 1800s for isinglass production, and has been regulated by the Indian government under the Harmonized System since 2002. Increasing demand from East Asia has driven fishing of croakers in particular, fueling an auction market in the major fishing and export ports Chennai, Kolkata, Mumbai and Veraval. There is little domestic Indian demand for fish maw. Bangladesh has a developing fish maw trade in the Karnaphuli delta targeting the high-value maws of Johnius coitor (datina koral) and Pomadasys argenteus, and Indian salmon. Less valuable but still traded fish maw species include Pangasius hypophthalmus, Labeo rohita, Catla catla, Wallago attu, and Leptomelanosoma indicum.
While acutely effective however, tachyphylaxis has been found to occur with continuous administration of atomoxetine. The reasons for this tolerance are unclear. Though development for Alzheimer's disease was discontinued, perhaps due to negative trial findings, there has been continued interest in atomoxetine in the potential treatment of this disease as of 2025. It has also been studied to treat mild cognitive impairment or prodromal Alzheimer's disease. Atomoxetine is being studied for treatment of sleep apnea in combination with various other drugs including oxybutynin or aroxybutynin, trazodone, antimineralocorticoids like spironolactone, an orexin receptor antagonist, pimavanserin, acetazolamide, dronabinol (Δ9-tetrahydrocannabinol; THC), fesoterodine, and zolpidem. Atomoxetine has been studied for reducing appetite and promoting weight loss in people with obesity, with mixed results.
Mortality was 5.7% with gemtuzumab and 1.4% without the agent (16/283 = 5.7% vs 4/281 = 1.4%; P = .01). In June 2010, Pfizer withdrew gemtuzumab ozogamicin from the market at the request of the US FDA. However, some other regulatory authorities did not agree with the FDA decision, with Japan's Pharmaceuticals and Medical Devices Agency stating in 2011 that the "risk-benefit balance of gemtuzumab ozogamicin has not changed from its state at the time of approval". In 2017, Pfizer reapplied for US and EU approval, based on a meta-analysis of prior trials and results of the ALFA-0701 clinical trial, an open-label Phase III trial in 280 older people with AML. In September 2017, gemtuzumab ozogamicin was approved again for use in the United States and in the European Union.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.